Peripheral biomarkers of neuroinflammation in Alzheimer’s disease and vascular dementia
Biochemical Pharmacology · 2026-08 · 250 · 118077
DOI: 10.1016/j.bcp.2026.118077 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2026-08. Verfasst von Xiaoxue Ouyang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore S117600 Singapore; School of Medicine, Tsing…. Hauptthemen laut MEDLINE: Dementia, Vascular, Alzheimer Disease, Neuroinflammatory Diseases, Inflammation Mediators. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 339 Literaturangaben. Gefördert von: National Medical Research Council, National Health and Medical Research Council.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) and vascular dementia (VaD) are the two commonest causes of dementia in older adults and frequently coexist as mixed neurodegenerative-cerebrovascular pathology. Although AD is classically defined by amyloid-β (Aβ) deposition and tauopathy, and VaD primarily by hypoperfusion-associated small vessel disease, both conditions involve chronic, dysregulated neuroinflammation. Evidence suggests that neuroinflammation is not merely a downstream response to tissue injury, but actively participates in the bidirectional pathological loop linking Aβ aggregation, tau hyperphosphorylation, and vascular dysfunction. These interacting mechanisms represent a rich reservoir of accessible biomarkers that may serve as indicators of disease activity, prognosis, and therapeutic target engagement. This focused review summarises key neuroinflammatory mechanisms that support peripheral biomarker development in AD and VaD, with emphasis on glial activation markers, cytokines, chemokines, inflammasome-related molecules and emerging exosome-derived candidates. We further discuss the growing role of ultrasensitive immunoassay and multiplex platforms, including single molecule array and proximity extension assays, in enabling the detection of low-abundance blood-based biomarkers and multi-marker inflammatory signatures. Although current findings are promising, their clinical translation remains limited. Existing studies often report altered inflammatory marker levels without sufficient validation of their diagnostic, distinguishing, prognostic, or pharmacological utility. Moreover, generalisability is constrained by cohort heterogeneity, limited VaD-specific evidence, variable assay platforms, demographic and systemic confounders, and consequently the absence of harmonised clinical thresholds. We therefore evaluate the translational potential of single biomarkers and emerging multi-marker panels, while emphasising the need to distinguish biomarker readouts from druggable inflammatory pathways and to validate these approaches in well-phenotyped AD, VaD, and mixed dementia cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore S117600 Singapore; School of Medicine, Tsinghua Medicine, Tsinghua University, 100084 Beijing, China.
- Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore S117600 Singapore.
- Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore S117600 Singapore; Memory Aging and Cognition Centre, National University Health System, Singapore S117599 Singapo…
- School of Pharmacy, Sungkyunkwan University, Suwon 16419, the Republic of Korea.
- School of Pharmacy, Sungkyunkwan University, Suwon 16419, the Republic of Korea; La Trobe Institute for Molecular Science, Department of Microbiology, Anatomy, Physiology and Pharmacology, School of Agriculture, Biomedi…
- Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore S117600 Singapore; Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National U…
Förderung
- National Medical Research Council
- National Health and Medical Research Council
Zitieren
APA
Ouyang, X., Chia, R. S. L., Chai, Y. L., Chong, J. R., Sim, M. A., Jo, D. G., Arumugam, T. V., Sethi, G., Dawe, G. S., Chen, C. P., & Lai, M. K. P. (2026). Peripheral biomarkers of neuroinflammation in Alzheimer’s disease and vascular dementia. Biochemical Pharmacology, 250, 118077. https://doi.org/10.1016/j.bcp.2026.118077
Vancouver
Ouyang X, Chia RSL, Chai YL, Chong JR, Sim MA, Jo DG, et al. Peripheral biomarkers of neuroinflammation in Alzheimer’s disease and vascular dementia. Biochemical Pharmacology. 2026;250:118077. doi:10.1016/j.bcp.2026.118077
BibTeX
@article{Ouyang2026,
author = {Ouyang, Xiaoxue and Chia, Rachel S L and Chai, Yuek Ling and Chong, Joyce R and Sim, Ming Ann and Jo, Dong-Gyu and Arumugam, Thiruma V and Sethi, Gautam and Dawe, Gavin S and Chen, Christopher P and Lai, Mitchell K P},
title = {Peripheral biomarkers of neuroinflammation in Alzheimer’s disease and vascular dementia},
journal = {Biochemical Pharmacology},
year = {2026},
volume = {250},
pages = {118077},
doi = {10.1016/j.bcp.2026.118077}
}
EUVIMED